Q1 2025 Tactile Systems Technology Inc Earnings Call Transcript
Key Points
- Total revenue grew 0.3% year over year to $61.3 million, with a significant 22% increase in airway clearance revenue.
- Gross margins improved by 290 basis points year over year, indicating better cost management and product design improvements.
- The company ended the quarter with a strong cash position of $83.6 million, despite a $10.7 million decrease due to stock buybacks.
- The launch of the Salesforce CRM module is expected to enhance sales efficiency and data-driven decision-making.
- Strong growth and adoption of the Nimbl product, which is outpacing the broader lymphedema market growth.
- Lymphedema business line revenue declined by 3% year over year, impacted by sales headcount vacancies and lower sales productivity.
- Adjusted EBITDA decreased by 125% year over year due to planned investments in technology and order processes.
- The transition to the new Salesforce CRM module temporarily impacted sales productivity more than anticipated.
- Operating expenses increased by 8% to $49.9 million, driven by strategic technology investments.
- Net loss increased by 35% to $3 million, or $0.13 per diluted share, compared to the previous year.
Welcome, ladies and gentlemen, to the first-quarter 2025 earnings conference call for Tactile Medical. (Operator Instructions) Please note that this conference call is being recorded and will be available on the company's website for replay shortly.
I would now like to turn the call over to Sam Benzinger, Investor Relations at Gilmartin Group, for a few introductory comments. Please go ahead.
Good afternoon and thank you for joining the call today. With me from Tactile's management team are Sheri Dodd, Chief Executive Officer; and Elaine Birkenmeier, Chief Financial Officer.
Before we begin, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties. These could cause actual results to differ materially from those indicated, including those identified in the risk factor section of our annual report of Form 10-K, as well as the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
